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The utrophin gene codes for a large cytoskeletal protein closely related to dystrophin which, in the absence of 
dystrophin, can functionally substitute it. Utrophin is transcribed by two independently regulated promoters  
about 50 kb apart. The upstream promoter is TATA-less and contains a functional GABP binding site which, in 
muscle, restricts the promoter activity to post-synaptic nuclei. Transient transfections analysis 
of mutant promoters in rhabdomyosarcoma cells showed that the upstream promoter contains three 
functional GC elements that are recognized by Sp1 and Sp3 factors in vitro. Co-transfections of the promoter 
with Sp1, Sp3 and GABP factors in Drosophila SL2 Schneider cells, which lack of endogenous Sp factors , 
demonstrated that both Sp1 and Sp3 are positive regulators of the utrophin promoter and that they activate 
transcription synergistically with GABP. Consistent with this result, we observed physical interaction of both Sp 
factors with the GABPa subunit in vitro. Functional domain interaction analysis of Sp1 and Sp3 revealed 
that both factors interact with GABPa through their DNA binding zinc  finger domain. The modulation and 
correct interaction between Sp1, Sp3 and GABP in muscle cells may be critical for the regulation of the 
utrophin promoter, and provide new targets for therapies of Duchenne muscular  dystrophy. 
  




The utrophin gene (also named dystrophinrelated gene) is an autosomal homologue of dystrophin 
(Love et al., 1989), which when mutated is responsible for Duchenne and Becker muscular  
dystrophies (DMD and BMD, respectively). Utrophin is transcribed in a large mRNA of 13 kb  
coding for a 395 kDa protein, with up to 73% of amino acid identity with dystrophin in important 
functional domains (Grady et al., 1997; Pearce et al., 1993). Functional substitution of utrophin with  
dystrophin in mice has demonstrated that a cure of DMD and BMD up-regulating the utrophin gene in 
patients is conceivable (Campbell & Crosbie, 1996; Deconinck et al., 1997; Grady et al., 1997; Rafael  
et al., 1998; Tinsley et al., 1996, 1998). Utrophin isexpressed ubiquitously, although in adult skeletal  
muscle its expression is mainly restricted to neuromuscularjunctions (Gramolini et al., 1997; Khurana  
et al., 1990; Scho®eld et al., 1993). Utrophin is transcribedby two independently regulated promoters  
(Burton et al., 1999; Dennis et al., 1996). Theupstream promoter is a TATA-less promoterassociated with a CpG 
island. It contains severalGC sequences which are putative Sp factor binding 
sites, and a functional N box (Dennis et al., 1996).This promoter is also under the control of a downstream 
utrophin enhancer (DUE) localised at about 9 kb within the second intron (Galvagni & Oliviero, 2000). A second 
promoter is localized about 50 kb further downstream, which gives rise to a utrophin with a different N-
terminal domain (Burton et al., 1999). Both promoters drive a wide distribution of utrophin transcri pts with 
overlapping expression in most tissues. The upstream utrophin promoter is mostly expressed in skeletal  
muscle, while the intronic promoter is more active in heart muscle (Burton et al., 1999; Love et al.,  
1991). 
The upstream utrophin promoter in cultured muscle cells responds by two- to threefold induction 
to treatment with heregulin or by the transfection of the Ets -related GABP factor (Gramolini et al., 
1999; Khurana et al., 1999). GABP has been reported to activate several viral and cellular pro moters 
(Fromm & Burden, 1998; LaMarco et al., 1991; Thompson et al., 1991; Triezenberg et al.,  
1988; Virbasius et al., 1993; Watanabe et al., 1993). In response to heregulin, the GABPa protein level  
is increased and both a and b subunits are phosphorylated (Schaeffer et al., 1998). GABP activates 
transcription synergistically with several factors, including Sp1, and has been demonstrated to interact 
directly with ATF and HCF factors (Ding et al., 1999; Dittmer et al., 1994; GeÂgonne et al., 1993; 
Rosmarin et al., 1998; Sawada et al., 1999; Vogel & 
Kristie, 2000). 
The Sp family of transcription factors is composed of four zinc finger proteins Sp1 -4, which in 
addition to the conserved DNA-binding domain, contain a glutamine-rich activation domain at the 
N-terminal region. Sp1, Sp3 and Sp4 recognise the consensus GC box element with identical af®nity  
(Hagen et al., 1992, 1994). Sp4 expression is most abundant in neuronal tissues (Supp et al., 1996),  
while Sp1 and Sp3 are both ubiquitously expressed 
(Dynan & Tjian, 1983a,b; Hagen et al., 1994; Kingsley & Winoto, 1992). Sp1 -de®cient embryos 
die after day 10 of embryonic development, while Sp3-deficient mice die at birth as a result of respiratory 
failure (Bouwman et al., 2000; Mari n et al., 
1997). Knockout mice phenotypes suggest that both factors have functional redundancy during  
early embryo development but exert distinct functions at later developmental stages. Sp1 binding to  
G á C-rich sequences are found in close proximity of transcriptional start sites and in enhancers  
(Pugh & Tjian, 1990). Accordingly, Sp1 has been shown to be associated both with general coactivators  
and with several promoter-speci®c transcription activators (Hoey et al., 1993; Kardassis 
et al., 1999; Lee et al., 1993; Rotheneder et al., 1999; Ryu et al., 1999; Seto et al., 1993). Sp3 has been  
shown to activate several promoters. It also seems to act as a repressor, since it also contains an  
inhibitory domain (Hagen et al., 1994; Liang et al., 1996; Majello et al., 1997; Udvadia et al., 1995; Zhao 
& Chang, 1997). Here, report the identi®cation and characterisation 
of functional GC sites present on the upstream utrophin promoter. Using in vitro binding 
experiments and transient transfections , we demonstrated that both Sp1 and Sp3 act as activators  
and co-operate with GABP to activate the utrophin promoter. We propose that the synergistic  
transcriptional activation observed is due to direct physical interaction of GABP with both Sp1 and  
Sp3, and mapped it to the a-subunit of GABP and the DNA-binding zinc ®nger domain of both Sp1 
and Sp3 factors. 
  
Results 
Sp1 and Sp3 bind to the utrophin promoter The utrophin promoter is a TATA-less promoter 
rich in GC elements (Dennis et al., 1996). To identify which GC boxes are functionally relevant for 
the promoter activity, we ®rst performed a DNA footprinting assay with recombinant Sp1 using 
DNA fragments spaning the promoter region from ÿ352/ á 47 as probes. Sp1 protection from DNase 
I revealed three main protected sites identi®ed as S1 (ÿ73/ ÿ 27), S2 (ÿ114/ ÿ 96) and S3 (ÿ151/ 
ÿ 135) (Figures 1 and 2). Interestingly, not all  the putative Sp1 sites on the promoter are recognised  
by Sp1 in vitro. The proximal S1 GC element is a tandem repeat of three non-canonical GC boxes, 
while the distal S2 and S3 elements are each composed of partially overlapping Sp1 consensus sites  
(Figure 2). To analyse nuclear factors binding to these elements on the utrophin promoter, we 
labelled the three probes containing the protected Sp1 sites and performed electrophoretic mobility 
shift assays (EMSA) with nuclear extracts from rhabdomyosarcoma RD cells. All  probes formed 
similar complexes that were named C1-4 (Figure 3). In addition to the complexes common to all  three 
probes, the DNA fragment S1 showed the formation of the slower migrating complex C5. 
Retarded complexes were speci®cally competed with an excess of unlabelled homologous oligonucleotides,  
while non-speci®c oligonucleotides did not affect the formation of the retarded bands (Figure 3(a)). All  
complexes were strongly reduced and supershifted with anti -Sp1 or anti-Sp3 antibodies 
(Figure 3(b)). Speci®cally, complexes C1-3 and C5 were inhibited and supershifted with anti- Sp3 antibodies, 
while the complex C4 was inhibited and supershifted with antibodies anti -Sp1. The presence of multiple bands 
containing Sp3 is not surprising, since Sp3 has been described to be expressed in at least three variants with 
different molecular sizes in several tissues (Kennett et al., 1997). The slower migrating band C5 that is  
formed with probe S1 (Figure 3(a) and (b), lanes 1) must contain more that one Sp3 factor, since this  
probe contains three protected tandem GC boxes (Figures 1 and 2). Retarded bands with slower 
mobility than C5 on the S1 probe, which could be observed with longer exposure, were reduced with  
both anti-Sp1 and anti-Sp3 antibodies (data not shown), suggesting the formation of higher molecular  
mass complexes. Sp1 and Sp3 activate the utrophin promoter while the distal S2 and S3 elements are each 
composed of partially overlapping Sp1 consensus sites (Figure 2). To analyse nuclear factors binding to  
these elements on the utrophin promoter, we labelled the three probes  containing the protected 
Sp1 sites and performed electrophoretic mobility shift assays (EMSA) with nuclear extracts from 
rhabdomyosarcoma RD cells. All  probes formed similar complexes that were named C1 -4 (Figure 3). 
In addition to the complexes common to all  three probes, the DNA fragment S1 showed the formation 
of the slower migrating complex C5. Retarded complexes were speci®cally competed 
with an excess of unlabelled homologous oligonucleotides, while non-speci®c oligonucleotides did 
not affect the formation of the retarded bands (Figure 3(a)). All  complexes were strongly reduced 
and supershifted with anti -Sp1 or anti-Sp3 antibodies (Figure 3(b)). Speci®cally, complexes C1-3 
and C5 were inhibited and supershifted with anti - Sp3 antibodies, while the complex C4 was inhibited 
and supershifted with antibodies anti -Sp1. The presence of multiple bands containing Sp3 is not 
surprising, since Sp3 has been described to be expressed in at least three variants with different 
molecular sizes in several tissues (Kennett et al., 1997). The slower migrating band C5 that is  
formed with probe S1 (Figure 3(a) and (b), lanes 1) must contain more that one Sp3 factor, since this  
probe contains three protected tandem GC boxes (Figures 1 and 2). Retarded bands with slower  
mobility than C5 on the S1 probe, which could be observed with longer exposure, were reduced with  
both anti-Sp1 and anti-Sp3 antibodies (data not shown), suggesting the formation of higher molecular  
mass complexes. 
 
Sp1 and Sp3 activate the utrophin promoter binding to GC boxes 
 
To test the functional role of GC elements, we generated mutants corresponding to the S1, S2 or  
S3 sites. Wild-type and mutant utrophin promoters  in front of the CAT reporter gene were transfected 
into RD cells. As shown in Figure 4, the deletion of the proximal S1 site affected utrophin promoter  
activity by over 60 %, while mutations of either S2 or S3 sites affected utrophin promoter function in  
RD muscle cells by 30 and 20 %, respectively. Direct activation mediated by Sp1 and Sp3 on 
the utrophin promoter was tested in Drosophila Schneider SL2 cells as these cells lack Sp-like 
activity. We therefore transfected the wild-type and mutant utrophin-CAT constructs in these cells  
along with a Drosophila expression vector carrying either the Sp1 (pPacSp1) or Sp3 (pPacUSp3) cDNA. 
Co-transfection of pPacSp1 with the utrophin wildtype promoter enhanced the promoter activity in  
SL2 cells ca 25-fold (Figure 5). Thus, Sp1 factor is ufficient to activate the utrophin promoter in SL2 
cells. By transfecting the promoter carrying the deletion of the proximal S1 binding site we 
observed a strong reduction of the utrophin promoter activity, while mutation of S2 affected  
the promoter activity in SL2 cells, but to a les ser extent. Co-transfection of the wild-type and mutant 
promoters together with Sp3 expression vector demonstrated that this factor is also an activator,  
albeit at weaker activity when compared with Sp1, since in the same conditions, Sp3 was activating 
the utrophin promoter of about five- to sixfold (Figure 5). 
 
Sp1 and Sp3 activate the utrophin promoter in co-operation with GABP 
 
The previous experiment demonstrated that both Sp1 and Sp3 activate the utrophin transcription in  
the heterologous SL2 cells. However, it was previously shown that Sp3 can act either as an activator  
or as a repressor in different promoter settings (Fandos et al., 1999; Hagen et al., 1994; Kennett 
et al., 1997; Liang et al., 1996; Majello et al., 1997; Udvadia et al., 1995; Zhao & Chang, 1997). In 
order to test the activity of these factors in muscle cells we transfected either Sp1 or Sp3 under the 
control of the CMV promoter in RD cells. Although in these cells we could not observe high levels of  
activation due to the presence of endogenous factors, by transfecting increasing amounts of either  
Sp1 or Sp3 expression vector we observed a low, but reproducible, increase of utrophin transcription  
with both factors (Figure 6). These results allow us to exclude the possibility that the utrophin 
promoter Sp3 acts as a negative regulator of Sp1 activation. 
It has been previously shown that the utrophin promoter contains a functional N box recognised  
by GABP (Gramolini et al., 1999; Khurana  et al., 1999). As Sp1 and GABP have been shown to cooperate 
in the transcriptional activation of several promoters and enhancers (GeÂgonne et al., 1993; 
Nuchprayon et al., 1999; Rosmarin et al., 1998), we analysed the the effect of Sp1 and Sp3 activation  






The upstream utrophin promoter is a typical TATA-less promoter rich in GC residues. It contains  
a functional N box, recognised by GABP, which has been demonstrated to confer a promoter  
response to heregulin (Gramolini et al., 1999; Khurana et al., 1999). We now report the identifi cation and 
characterisation of three functionally distinct GC elements on the promoter: a proximal  
element composed of three tandem repeated GC boxes, which behaves as a basal promoter element, 
and two upstream GC boxes required for full  promoter activation. All  three GC elements of the 
utrophin promoter are recognised by the ubiquitous Sp1 and Sp3 factor s. Sp1 was originally 
defined as a proximal promoter factor, required for basal promoter activity, which was thought to  
function only when located in close vicinity from the transcription start site. However, early experiments  
also showed that Sp1 can function from distant sites as a weak activator (Courey et al., 1989). 
In l ine with these observations, the utrophin GC elements, recognised by Sp1 as well as Sp3 factors,  
was shown to be necessary for utrophin promoter activity. Although a clear functional di stinction 
between these elements cannot be made, the mutation of the proximal GC tandem repeats  
strongly impaired the promoter basal activity both in rhabdomyosarcoma and in Sp1/Sp3 transfected  
Drosophila SL2 cells, while mutations in the distal sites were less effective in the same conditions. 
Thus, the function of the proximal GC boxes cannot be entirely replaced by the upstream elements  
in spite of the fact that all  three GC elements are extended footprint, and gel retardation experiments  
revealed the formation of slower migrating complexes that are supershifted with anti -Sp1/Sp3 
antibodies. Knockout experiments showed distinct functions of Sp1 and Sp3 during development (Bouwman  
et al., 2000; Marin et al., 1997). This could be due to the fact that Sp3 can act as an activator or a repressor 
in different promoter contexts (Fandos et al., 1999; Hagen et al., 1994; Liang et al., 1996; Majello  
et al., 1997; Udvadia et al., 1995; Zhao & Chang, 1997). On the utrophin promoter, transient transfection  
experiments revealed that both Sp1 and Sp3 behaved as activators, with Sp1 being more 
active than Sp3 in both Drosophila and muscle RD cells. 
It has been previously demonstrated that GABP activates the utrophin promoter (Gramolini et al.,  
1999; Khurana et al., 1999). Here, we demonstrated 
that GABP synergises with both Sp1 and Sp3 for utrophin promoter activation, and that both Sp1  
and Sp3 directly interact with GABP in vitro and in vivo. Mapping the Sp1 and Sp3 interaction  
domains revealed that both Sp factors interact via their zinc finger DNA-binding domain. 
The GABP factor is composed of one Ets -related GABPa subunit and an ankyrin repeat-containing 
GABPb subunit (Batchelor et al., 1998; LaMarco et al., 1991; Thompson et al., 1991; Watanabe et al.,  
1993). GST pull -down experiments revealed that only the GABPa subunit interacts with both Sp1  
and Sp3 factors. This result was confirmed by immunoprecipitation experiments in which GABPa  
co-immunoprecipitated with either Sp1 or Sp3. 
Thus, our experiments suggest that the synergy between GABP and Sp1/Sp3 is due to direct interaction 
between the zinc ®nger domain of either Sp1 or Sp3 and the GABPa subunit. Although we 
observe direct interaction only with GABPa, in order to activate transcription synergistically   
GABPa/b subunits are required. This result is in l ine with the observations that the b-subunit is  
necessary both for DNA binding of the a-subunit and for transactivation of the heteromeric GABP 
factor (Batchelor et al., 1998; Guneja et al., 1995, 1996; Thompson et al., 1991). Thus, the direct interaction 
between Sp1/Sp3 and GABPa subunit is able to recruit to the utrophin promoter the active 
GABPa/b complex. Our experiments also suggest that post-translational  
modifications are not required for interaction between GABP and Sp1/Sp3, since we observed 
direct binding of these factors synthesised in vitro. Interestingly, it has been previously demonstrated  
that stimulation of muscle cells with heregulin increases GABPa protein levels besi de inducing the 
phosphorylation of both a and b-subunits (Altiok et al., 1997; Fromm & Burden, 1998; Schaeffer et al., 
1998). Moreover, using transient transfection experiments it was also demonstrated that the co-transfection 
of GABP cDNAs, along with the utrophin promoter in muscle cells, resulted in the activation 
of the promoter transcription to levels comparable to those obtained with cell  treatment with heregulin  
(Gramolini et al., 1999; Khurana et al., 1999). 
Thus, the increase of GABP per se is sufficient to induce utrophin up-regulation, suggesting that 
GABPa is present in l imiting amounts in muscle cells. Small increase of GABPa can, when interacting 
with GABPb, synergise with either Sp1 or Sp3 and increase utrophin transcription. 
In addition, in post-synaptic nuclei it has been shown that Sp1 is phosphorylated in response to 
synaptic-speci®c stimuli suggesting that, upon phosphorylation, Sp1 may increase its binding to  
DNA via protein-protein interactions, facilitating the formation of Sp1 multimers and/or increasing 
its interaction with other proteins (Alroy et al., 1999). Thus, it is possible that Sp1 phosphorylation  
may allow a fine modulation of the utrophin promoter in response to extracellular stimuli. Further  
studies will  address the role of Sp and GABP phosphorylations with respect to their interaction. This  
could be relevant in view of the possible regulation of the utrophin transcription by pharmacological  
means in DMD and BMD patients. 
